Q3 2024 Cantargia AB Earnings Call Transcript
Key Points
- Cantargia AB (FRA:7V3) received FDA clearance to start a leukemia study, fully funded by a grant from the US Ministry of Defense.
- Positive clinical data was presented at the ESMO Congress for nadunolimab combination therapy, showing promising results after relapse PD1 inhibitor therapy.
- The CAN10 program has shown very good safety results and positive effects on biomarkers and pharmacodynamics in Phase I trials.
- Nadunolimab has demonstrated increased tolerability when combined with chemotherapy, reducing neuropathy side effects.
- The company is developing diagnostic tests to identify subgroups of patients with high IL1RAP, potentially improving treatment outcomes in pancreatic and lung cancer.
- Cantargia AB (FRA:7V3) is operating at a lower level of activity and spending compared to previous years, with R&D expenses down by over 40%.
- The company has a cash balance of approximately SEK60 million, necessitating a rights issue to fund future activities.
- The rights issue, if fully subscribed, will only provide funding until the middle of 2026, indicating potential future financial constraints.
- The Phase II study design for CAN10 is not yet finalized, and funding for this phase is not included in the current fundraising.
- The company had to change its strategy for the pancreatic cancer program due to new regulatory guidelines, delaying progress.
Thanks a lot. It's with the great pleasure we are here to present our Q3 report from Cantargia. It's been an exciting period with rich news flow. And if we quickly summarize the news flow during or after this period, we've seen that we made progress in both of our clinical programs, both in nadunolimab and the CAN10 program and in nadunolimab program, some of the material events has been that the FDA gave us clearance to start a leukemia study, which is also fully funded by a grant from the US Ministry of Defense.
We got the first results in the randomized Phase II trial more and more clearly defined when to expect, and it's going to be in the first half of 2025. So obviously, something to look forward to later on. We presented new clinical data first at the ESMO Congress on nadunolimab combination therapy after relapse PD1 inhibitor therapy. And that shows some very exciting data points, and we'll go through that in a second.
And we also did a number of clinical trials that were started in 2021, but due to changing market
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
